Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.51 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 2/20 | 0.47 |
| ▸ | CTSC | P53634 | 4/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | CHUK | O15111 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | IDH2 | P48735 | 2/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31485515 | 0.84 | CSNK2A1 (0.49) | CSNK2A1PTK6EGFR | |
| SCHEMBL31356303 | 0.84 | LATS1 (0.56) | CSNK2A1ABCG2EGFRGRM4 | |
| SCHEMBL31485477 | 0.81 | ABCG2 (0.47) | CSNK2A1ABCG2CHUKEGFR | |
| SCHEMBL31485528 | 0.81 | CSNK2A1 (0.53) | CSNK2A1PTK6ABCG2CHUKEGFR | |
| SCHEMBL31485519 | 0.81 | IDO1 (0.45) | CSNK2A1TDO2EGFR | |
| SCHEMBL31356292 | 0.81 | PTK6 (0.53) | CSNK2A1PTK6KIF11CTSCABCG2 | |
| SCHEMBL31356307 | 0.80 | CHUK (0.45) | CSNK2A1ABCG2CHUK | |
| SCHEMBL31485510 | 0.78 | LATS1 (0.39) | CSNK2A1CHUKEGFR | |
| SCHEMBL31485537 | 0.77 | LATS1 (0.53) | TDO2CHUKEGFR | |
| SCHEMBL31485514 | 0.77 | CSNK2A2 (0.44) | CSNK2A1TDO2CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12269826-B1 | 7H-pyrido[4′,3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds as CK2 inhibitors | King Faisal University (SA) | 2025-04-08 | — | — | US | claimed |
| US-12269826-B1 | 7H-pyrido[4′,3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds as CK2 inhibitors | King Faisal University (SA) | 2025-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12269826-B1 | 7H-pyrido[4′,3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds as CK2 inhibitors | CKS2, CSNK1G1, CSNK2A3 | CSNK2A1 5/4885PTK6 292/4885KIF11 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.